Evidence map›Paper›PMID 35684339›Full record

ArticleMolecules (Basel, Switzerland)2022

Ursolic Acid Enhances the Sensitivity of MCF-7 and MDA-MB-231 Cells to Epirubicin by Modulating the Autophagy Pathway.

Zhennan Wang, Pingping Zhang, Huan Jiang, Bing Sun, Huaizhi Luo, Aiqun Jia

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Dual role of autophagy in bone metastasis: mechanistic insights and therapeutic targeting.American journal of clinical and experimental urology · 2025
    Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. F1000Research · 2024
    Article
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Zhennan WangSchool of Environmental and Biological Engineering, Nanjing University of Science and Technology, Nanjing 210094, China.
Pingping ZhangState Key Laboratory of Marine Resource Utilization in South China Sea, School of Pharmaceutical Sciences, Hainan University, Haikou 570228, China.
Huan JiangSchool of Environmental and Biological Engineering, Nanjing University of Science and Technology, Nanjing 210094, China.
Bing SunSchool of Environmental and Biological Engineering, Nanjing University of Science and Technology, Nanjing 210094, China.
Huaizhi LuoSchool of Environmental and Biological Engineering, Nanjing University of Science and Technology, Nanjing 210094, China.
Aiqun JiaSchool of Environmental and Biological Engineering, Nanjing University of Science and Technology, Nanjing 210094, China.
Nanjing University of Science and Technology · CNHainan University · CN

Funding

Hainan Provincial Natural Science Foundation of China 221CXTD434National Natural Science Foundation of China 82160664
6 · The paper itself

Abstract

Breast cancer is the leading cause of cancer death among women in the world, and its morbidity and mortality are increasing year by year. Epirubicin (EPI) is a commonly used drug for the treatment of breast cancer but unfortunately can cause cardiac toxicity in patients because of dose accumulation. Therefore, there is an urgent need for new therapies to enhance the sensitivity of breast cancer cells to EPI. In this study, we found ursolic acid (UA) can significantly improve the drug sensitivity of human breast cancer MCF-7/MDA-MB-231 cells to EPI. Next, we observed that the co-treatment of UA and EPI can up-regulate the expression of autophagy-related proteins Beclin-1, LC3-II/LC3-I, Atg5, and Atg7, and decrease the expression levels of PI3K and AKT, which indicates that the potential mechanism should be carried out by the regulating class III PI3K(VPS34)/Beclin-1 pathway and PI3K/AKT/mTOR pathway. Furthermore, we found the autophagy inhibitor 3-methyladenine (3-MA) could significantly reverse the inhibitory effect of co-treatment of UA and EPI on MCF-7 and MDA-MB-231 cells. These findings indicate that UA can dramatically enhance the sensitivity of MCF-7 and MDA-MB-231 cells to EPI by modulating the autophagy pathway. Our study may provide a new therapeutic strategy for combination therapy.

Indexed as

Breast NeoplasmsProto-Oncogene Proteins c-aktApoptosisAutophagyBeclin-1Cell Line, TumorEpirubicinFemaleHumansMCF-7 CellsPhosphatidylinositol 3-KinasesTriterpenesUrsolic AcidBeclin-1EpirubicinPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktTriterpenesUrsolic Acidautophagybreast cancerdrug sensitivityepirubicinursolic acid

Identifiers

PMID35684339
PMCPMC9182048
OpenAlexW4281486430

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.